0:04
Hello everyone. Welcome to our uh obesity expert panel.
0:11
This is a chance for our faculty who covered obesity at ACR Convergence 2027 last week in Orlando to convene compare notes and discuss what we thought were some of the more interesting aspects of obesity.
0:28
a really hot area, a lot going on that will benefit a lot of people, but incredibly it's going to benefit a lot of our patients in rheumatology.
0:37
Uh, we have a really good panel. I'm going to ask them to introduce themselves.
0:42
I'm Jack Kush in Dallas, Texas. Uh, Mike Putman.
0:44
Hi, I'm Mike Putman, Milwaukee, Wisconsin.
0:47
Akquil. Hi, I'm Akil Sud at Washington University in St.
0:53
Louis. And Jiha. Hi, I'm Ji Halei from Michigan.
0:56
Excellent. All right. So, um I'm gonna take the u moderator's privilege and lead the discussion for the first time uh and talk about what I think might have been what I think is maybe the most important study or the most impactful study um uh from the meeting.
1:16
It was I believe a day one plenary session uh abstract0871 the triumph 4 study read a true tide in neoa uh patients who have
1:28
who are obese uh Dr. Dr. Phil Conahan from leadeds presented this trial a 68-week phase three trial of this triple agonist therapy an increeton
1:41
therapy called retatride it inhibits GIP GLP1 and glucagon it's a once a week injection you know we had these single agonist GLP1s and dual
1:51
agonist which is trappepide and now these triple agonist they try to get a better drug maybe less side effects maybe more weight loss So,
1:58
um, this study had 445 non-diabetic adults with a BMI of greater than 27 and a WMAC pain score of four to nine.
2:08
Couldn't be 10. Kelgrren Lawrence neoa damage of class two or three, grade two or three, but not four.
2:19
Uh, and they got placebo or retatride 9 milligrams or 12 milligrams.
2:23
The patients were bad. They had a mean BMI of over 40.
2:29
They had a mean weight of about 230 pounds.
2:34
Uh their baseline WMAC was nearly six. Um at the end of 68 weeks, the WMAC pain fell to uh um uh what was it?
2:43
Fell to 4.5 and 4.4 versus 2.4 in placebo.
2:50
Weight dropped by 26 to 29% um which was much better.
2:54
And they lost as much as 71 pounds in the 68 weeks.
2:56
50% pain reduction 86 and 78% versus 46% in placebo.
3:03
Again, uh reatrite even had lab benefits.
3:07
Uh high sensitivity CRP um was down 50% versus 25%.
3:14
Triglycerides also down. The usual side effects and nausea 38 to 40% whatever uh AES about 10% AES leading discontinuation 13 and 18% versus four.
3:26
This was, I think, a major thing for neoa patients who are obese.
3:31
Um, Michael, you talked about this earlier on in the week in your day one report.
3:36
What's your what was your takeaway on this or what how might this impact practice?
3:41
Oh man, I think this is a fun one and I love it because we have seen so many OA trials presented that were either failed or kind of successful but not really and then not FDA approved and finally getting to see one that just hit across the board and had a big difference is really really exciting.
4:00
Um I I can't get over wondering what is driving this.
4:02
If it's just unloading the knee. Is this that the knee is healthier because there's less weight?
4:08
Or is this that people just look great and are out and about and have much better quality of life?
4:12
Or is this something immune-based um something psychossematic, psychonurogenic that uh is actually a different thing entirely?
4:19
And uh I I wonder that I don't know if it matters, but I think about that every time that I see trials like this, and I've still been thinking about since the meeting.
4:27
Yeah, I don't know if it matters either.
4:29
I would say one thing that I I don't I haven't heard anyone say and you kind of hinted at it is once these people start to lose significant weight, it's a it's a downhill roller coaster.
4:40
They want to lose more weight and once it works, it really works.
4:45
So maybe, you know, losing the first 25 pounds, you know, might be all that you need to do.
4:49
But I want to know from our other panelists, does it really matter if this is weight loss and running around more or if this is an imologic anti-inflammatory effect?
4:59
What do you think, Gia? I mean, I think you can't argue like everybody was very shocked and pleased with these findings.
5:07
So, does it matter? I think us as scientists would like to know for our patients, does it matter?
5:11
Probably not really. And I think that makes me think clinically like where does this actually fit into the spectrum, right?
5:16
Like right now we're offering patients steroids and hyaluronic acid because they're cheaper and the ultimate fix is surgery.
5:23
In between that is this something that's ultimately mean patients don't need as much surgery or delay that time point.
5:29
I think that that's more my curiosity point right now.
5:31
Yeah. Uh Akquil, you've seen and you're going to talk about uh GLP1s uh in this session.
5:37
Um how impact impactful will this be on rheumatologists?
5:42
Yeah. Um, I think this will be a pretty impactful.
5:45
I mean, I think from just a day-to-day uh clinical practice standpoint, we see a lot of arthritis and especially OA.
5:53
And I mean, knee OA, I mean, I think it's it's quite prevalent among many of our patients.
5:57
And I think kind of the options we think of are just pain control, steroid injections, and then ultimately is seeing orthopedics for uh evaluation for knee arthoplasty.
6:07
I think the uh especially considering how G how obesity plays a significant role in um arthritis especially OA I think the the valing the
6:17
role of a GLP gip this reatride I think it's really um profound and really impactful I mean kind of alluding back is that it's
6:26
hard to say if it's anti-inflammatory or this is just more metabolic and the metabolic control the metabolic improvement is leading to the weight reduction
6:34
and less locking on as Mike alluded to Um I'd say it's more of that but kind of early to say at this time but
6:41
I think that it gives us another option uh for helping um man helping our patients um in terms of their uh pain related to
6:51
the knee arthritis knee osteoarthritis.
6:52
You know what I was surprised at is that we did a campaign um two months ago on obesity in the rheumatic diseases and I was shocked uh it was that was September.
7:04
I was shocked to see how many rheatologists are experts in obesity and have really embraced this thing.
7:12
And there's a lot of people that um want to know more.
7:13
So great research is needed to move the needle on this.
7:18
And the question is, will you have the time to manage these people and their obesity in addition to all that you're managing otherwise?
7:24
That's really a a hard decision that you're gonna have to make at the point of care.
7:29
Um let's go with Dr. Putman. What What did you like at the meeting, Mike?
7:33
Yeah, I'm gonna duck in on another GLP article because I think they're a lot of fun.
7:37
Uh my I wanted to talk about abstract 2942.
7:40
This is the together PSA trial which in my head is always together PA which doesn't make any sense [laughter] that evaluated the 17 inhibitor ixismab against ixismab and then the GLP tepatide which is a really interesting study design.
7:57
Um the initial reports of this were actually published earlier this um uh this year.
8:02
Uh so this is the 52- week data that was presented at the meeting.
8:04
Um and it looks like the benefits persisted.
8:06
You know to get in this trial you had to have active serotic arthritis.
8:10
Um these patients mostly failed at least two drug classes.
8:12
This like a tough tough group tough group.
8:14
Um they also had to be overweight or have like some overweight plus some cardtabolic issues.
8:20
So very [clears throat] good population to target.
8:22
Um the you know the main outcome for this there is actually ACR50 plus 10% weight loss which is kind of funny.
8:29
You know, nobody lost weight on the group that got ixismab by itself.
8:34
It was like 2%. And then the people got exchatid like 39% lost 10%.
8:39
So, you know, it's like a home run, you know, obviously.
8:41
But ACR50 alone was higher among people who got ixismab pluside.
8:47
And it was not like a little higher. It was 44 versus 16% at week 52.
8:51
So, that's a 28 point delta. That's a number treat of about three people to hit an ACR 50 at week 52.
8:58
I mean that would independently be enough to get you approved in seriatic arthritis and you know everyone here got 17 but that was in both groups.
9:06
So this is really the effect of adding the GLP-1 on top which is pretty cool.
9:10
Um they hit on facet fatigue hackdi all of that got better and then high sensitivity CRP also got better.
9:15
Same question is that you know better weight is that some additional impacts we don't totally know.
9:20
This is only week 52, so I think a main limitation, but um kind of another meeting or kind of another abstract at the meeting that I thought really hammered home the potential benefits of these for rheumatic diseases.
9:33
Yeah. So this is a a registration trial.
9:36
This is going to be was done with the idea it might be a new indication for tzepide.
9:42
Um and that would be a surprising and welcome thing.
9:47
Um Mike, you analyze a lot of these papers, especially you know u online and um where do you see a fault in this study?
9:54
I don't really see much in maybe the silly looking for weight loss interpepatide uh with I mean with the exacismab but I I is there a fault that might get in the way of this becoming um an approval study?
10:09
Yeah, I mean I think that the main concern here is just what are we actually studying here?
10:14
The ACR50 is a composite outcome measure that includes a lot of patient reported outcome measures.
10:18
Um so you know you really want to split that out and see which kinds of things got better.
10:23
A lot of the joint specific things also got better like minimal disease activity.
10:27
So I don't know I think that there is a true benefit to the disease itself here.
10:32
Um that'd be one hiccup. The other one is like so what are we going to do now?
10:35
Are these people going to stay on this for 10 years?
10:36
I mean it's not like their serotic arthritis is going to go away.
10:39
you know, if you lose the weight, you're down 100 pounds, maybe we can transition to diet and lifestyle, although not sure that always works.
10:46
Uh, but so if this is a disease control thing, what does the future for this look like?
10:50
And I think that's a big unanswered question.
10:52
It's a but it's a good problem to have, don't you think?
10:55
Right. So, u Aquil or Jihad, do you have a comment on this study?
11:00
Yeah, I think you raised the interesting point of I think this is probably the elephant in the room of everybody's mind is do you stay on GLP1 forever?
11:08
But in terms of your question about the study design, I think it's the fact that they studied tricepide and is achismab at the same time.
11:14
Right? So at the beginning the findings are great but you don't know is it coming from ismite alone or later and also in reality we don't often start our patients on two drugs at the same time.
11:25
So I think there was another actually um abstract together amplify which is a tweak on this study where you're introducing tzapatide like three months later.
11:34
So there's a little bit of a lag to really mimic more real world.
11:37
And there were two other posters on a smaller scale independent of the together study where they showed that actually on patients already established on biologic.
11:47
One was with 17. The other one was like any kind of biologic and targeted synthetic.
11:52
So it's actually even expanding beyond that to show that in very early signs and um preliminary data that adding on GLP-1 later still has additional benefits.
12:02
So I think there's still more to come but I think again mainstay is like as rheatologists we probably are going to start seeing more patients and start prescribing more of this for sure.
12:11
the idea of how long you stay on, what's the long term, I think once you get to an end point.
12:18
Um, I think that the endocrine people or the obesity people are figuring out that the patients will define for it.
12:23
First off, they don't want to take the shot every week.
12:25
You know, they t start spacing it out like people do with their, you know, their abbitasept and uh, you know, maybe they don't go off of it, but they do because if you go off them, you're going to gain the weight back.
12:37
That's absolutely clear. But finding a modified program as what we learned from September with our obesity imper imperative campaign.
12:43
Akquil, what do you think? Yeah. No, I echo e echo the same points as everyone made.
12:49
I think even with the GLP in combination with 17 and I think one thing is is that you know we're you know we're seeing that improvement in ACR50 but I kind of go back to the design of the study.
12:59
Um correct me if I'm wrong but I think it's that the assessors were blinded the patients were not.
13:03
And so I mean for I guess I'm what I'm really curious to kind of see is that is there improvement where exactly within the ACR50 are we seeing the improvement and could that could we be overestimating some of the findings as well?
13:16
I mean we are seeing findings pretty early on in the in the course um after starting the treatment and you know the follow-up is
13:24
at 52 weeks but I think um part of it being that um the if if the only assessors are blinded I mean that could
13:30
kind of influence the results in some way and even just the granularity of like which joints are improving is it kind of alluding back
13:37
to the reatite abstract is that we're seeing improvement in weightbearing joints.
13:39
I'm curious to see kind of where uh patient which joints are improving um for patients with with seratic arthritis.
13:47
Is it the more the weightbearing joints like hips, knees, ankles or less weight nonweavering joints that we're seeing that improvement?
13:53
And so kind of just details and granularity would be would be really interesting to know about.
13:57
Mike, final comment on this. Yeah, I I love that point so much.
14:03
I'm obsessed with unblinding. And I usually like to rag on open label studies with a outpoint that includes pros in it.
14:09
But look, I mean, how do you unblind a study where half the people cut 20, 30, 50 pounds?
14:14
I mean, everyone knows which group they're in when they lose that much weight.
14:18
And so, I've kind of thrown up my hands on this.
14:21
I don't even know if you can blind studies like this because it's kind of obvious whether or not you're getting the drug.
14:26
But I love I love unblinding as a point.
14:29
So, uh, totally agree with Kayen. So I've lived through this argument of like is it the weight loss?
14:34
Is it the psychiatric aspect? Is it an imologic anti-inflammatory aspect?
14:39
Uh and it reminds me after going through this many times to you know the the point is that we've learned more about drugs from bedside and then bench not bed to uh bench to bedside and it works great.
14:54
Now we'll try to figure it out. And that's what rheumatologists get hung up with.
14:56
this works great and now we want to know why.
14:58
And my my response to this is it don't matter.
15:03
You know, if you want to, you know, but is is that holding you back from doing this?
15:08
Um, my argument is going to be it doesn't matter.
15:12
I think with that, but then now that becomes an issue about how you're wired and how Kush is wired as opposed to the truth, which may be a long time coming and may require a a really detailed trial design to answer the question.
15:26
So we'll see going forward. Akquil, what's your your your next one?
15:29
Yeah. Uh thanks Jack. I think you know so mine is kind of building upon together the building upon the together PSA trial.
15:36
It's the abstract 0876. This is another plenary uh presented on Monday.
15:40
Essentially they looked at the real real world use of GLP1s in patients with rheumatoid arthritis and seratic arthritis and its impact on functional status
15:49
and they use the rise registry and essentially they identified patients with RA and PSA that were already on biologic demarss and that they were
15:59
then started on a GLP either semiglutide or tzepatide and then they valid their changes in their rapid three scores their patient global assessment as
16:08
well as their functional um status based on the MD hack.
16:10
back and then they separately looked at what are the odds of achieving a min minimal clinic minimal clinically important differences or MCID based on
16:20
predefined criteria in the rapid 3 as well as the individual components such as patient global assessment pain and function scores and so um you
16:28
know with the rise registry they had there's a large number of patients that were identified with RA or PSA on that were on a
16:36
GLP but essentially they looked at they had about a cohort of 1900 patients that were initi ated on GLP and that they had uh
16:43
readily available rapid three scores uh collected at serial time points and essentially they found that over a oneear over um the mean weight loss
16:54
in this cohort was about 15.6 6 pounds and then rapid 3 reduced by about 1.3 points.
16:58
And then when they did a multivariable regression models they found that the each 5% decrease in body weight uh rapidly reduced by.3 and uh
17:07
the individual components along with pain global assessment and reduction in function also improved at the at the follow period and they found that these
17:17
were all associated with higher odds of MCID or minimal clinically important differences both the composite rapid 3 as well as the component of pain
17:26
function and um uh um patient global assessment and um you know I think these findings are just overall really interesting and definitely same thing
17:35
go back to giving GP1 consideration and kind of looking at its uh relationship with patient reported outcomes but same thing does open a lot
17:45
of questions as well so this is interesting juaposed to the triumph study in neoa you know this is the moleh hill and that's the
17:56
mountain so there there was great associations here But why was it so small?
18:01
And let me do a setup for Mike Putman to and Jihad to comment on.
18:05
The rise registry has almost 17,000 patients.
18:09
They included they selected 1,800 of those people with RA and PSA.
18:13
Why so few that they had available data?
18:16
Uh and in the end a 5% reduction was associated with a.3 change in um in rapid three.
18:25
Um you know the rapid three is like is zero to 40 points or something.
18:30
Um and you know meaningful weight loss in PSA is uh is is 5%.
18:38
Um really meaningful is 10%. And and but this was you know.3 not even a point change in the rapid 3.
18:43
I I want to know why the the results were so meager.
18:48
It was it's great that they were significant.
18:50
Oh, by the way, I'm one of those irritating people with the microphone asking questions and the author uh the presenter said when they did other analyses, what was not significant was CI, which includes swollen joint count and CRP.
19:06
So, Mike, do you know what the limitations here were?
19:13
You know, I struggle with reports like this from real world data.
19:18
I mean sometimes it feels like we're just missing out on something um because the data is a little bit messier.
19:23
You have a little less confidence in what people actually got.
19:26
Perhaps a little less ascertainment of outcome measures.
19:30
Rise is a good registry. So it perhaps in a real world uh situation you are actually just seeing less benefit to these kinds of rapid 3 outcomes.
19:37
I like the rapid 3 a lot. We used to collect it in my fellowship and I think it's very tangible for patients.
19:42
So the other thought is that maybe that's just a next level up.
19:46
you know, your high sensitivity CRP is easy to hit on, but then if you're asking someone about these very specific behavioral things, they don't budge as much, which is a bummer, but uh I don't know.
19:57
I still was also think less benefit than I would have expected.
20:00
I want to remind the audience of what I learned during the vio hearings when there was a lot of registry data being thrown around
20:10
and uh Milton Packer a great epidemiologist said these studies are hypothesis generating only they are not proof of anything you know you you find
20:21
this kind of data you can now do the better study now if the better study is impossible to do that's what you're left with
20:28
but um this still isn't the complete and final answer.
20:31
Jiha, I echo what Michael says. I think knowing of rise is great and because we have so few registry or any real world data that has disease activity, but I think the reality is only like 30% of the whole data set has consistent measures.
20:44
And even then among practices, they don't all use the same measure.
20:49
And I think inertia and us practicing, I'm guilty of this too.
20:51
The ones that I record for are usually the ones who are either sicker or stable or the ones who just happen to have it and you continue.
20:57
So I think there's really a data issue here.
21:00
Um I think along with that is like I think this also gives the question is disease activity we see great results in the trials like the together PSA but is that really the patient experience like what domains are they really seeing the improvements in?
21:12
Is it some of the unmeasured like the fatigue um as well as depression or some of the more you know mood related things like that.
21:19
So I I agree with you. I think the effect size is rather small than what we would have expected to see, but I think again rise limitations are probably what's driving a lot of this potentially.
21:29
Okay. Uh Dr. Lee, what's one of the favorite ones you had on obesity from the meeting?
21:35
So, having spoken about the limitations of real world data, this one is too on it.
21:41
This is abstract number 0451. And I picked this because along with the theme of GLP1 with improvement in disease activity, I think there's more questions now about like what other outcomes is it improving?
21:53
And I think one of the bigger concern we have is along with weight loss comes muscle mass loss as well as increased risks potentially then of osteoporotic fracture.
22:02
So this was a study dur done out of the um Jefferson Einstein Philadelphia group and they used Trinidadex um global collaborative network data and we're seeing more and more of that.
22:14
It enrolled adults with RA who are overweight with BM micro than 25 or obesity based on ICD diagnosis.
22:21
And they did actually two separate D um analysis for RA patients with diabetes and RA patients without diabetes probably to get at the um
22:32
different indications for GLP1 prescribing and the outcome of interest was composite fracture including vertebral and hip fractures and also looking at any differences in
22:40
fall recorded in that data set.
22:42
They did do propensity score matching one-on-one based on demographic coorbidities and some medications although that list is not available and smoking which is a known um risk factor and they um did survival analysis.
22:57
So after matching they had 4,643 patients in the diabetic cohort and 2,479 in the non-diabetic and the results were slightly different based on diabetes status.
23:06
So among the diabetic group um there was no associated increase in the composite fracture.
23:12
The hazards ratio were rather small and also there was no um significant difference in terms of fall but there were differences in terms of there being lower vertebral fracture in the GLP group as well as lower hip fracture.
23:26
Now when it comes to the without the people without diabetes again no association with composite fracture and again the vertebral fracture rate was lower but then the hit fracture they just couldn't measure it because the incidence was rather low.
23:42
It is a smaller sample size but then falls um were also lower in the GLP group.
23:46
I like what they wrote in the um conclusion.
23:47
They say the potential skeletal protective effect of GLP-1 receptor agonist in osteoporetic RA population are tantalizing and warrant further prospective investigation.
23:59
Put that in your title. Um you'll get your poster will go to an oral presentation would be my suggestion.
24:06
Um what do you guys think of that Aquille?
24:09
Yeah, I think those are really interesting uh findings especially I mean thinking about GLP1 and uh the risk of uh osteoporotic hip fractures.
24:18
I mean the fact that you see an imp a reduction or improve or lower risk in those I mean I it makes me kind
24:24
of wonder is that with that weight reduction what does it allow our patients to do does it allow them to engage in better um
24:29
non-weightbearing exercises to improve bone health that is improving it like what is the downstream effects in terms of how we are reducing the risk
24:37
I mean I definitely do want to see longerterm follow-up uh with this data but I think that's really exciting really interesting kind of seeing
24:45
how it translates into clinical practice with that GOP1 that reduction in weight is that despite the concern for loss of muscle mass is there
24:53
improvement is that enabling our patients just to engage in activities that improve or optimize bone health.
24:59
Yeah, Mike. Yeah, interesting paper. I I do research with this database.
25:04
I it's a lot of fun, but the data is always a little bit questionable.
25:08
Um I thought this was relatively convincing with the caveat that these numbers are almost better than what you'd expect with bisphosphinate use.
25:16
And whenever you have someone you have an intervention that's not really targeted and there's heavy confounding with the use of a GLP-1 and it's kind of better than something that's more bioplausible, I always like take hit the brakes a little bit.
25:28
Uh but I would, you know, I would say that this is certainly possible that losing weight would reduce your falls, improve your fracture risk.
25:35
I think it's tantalizing, but I might stop there before I went all in on it.
25:40
Yeah. What I what I like a little bit about this data is the reminder especially for rheatologists if you're going to get into this
25:50
increant therapy and GLP1 use um it behooves you to become really good at counseling your patients about the muscle mass loss and that they're
25:58
going to have to go really for the GLP1s and all their newer versions to work better you got to get into lifestyle management in
26:07
a major way you know and changing their diets you know you can't just be the the injectable or the pill that's going to fix
26:13
your weight problem, changing your diet, um getting stronger, you know, these are all important caveats that are going to be a part of uh
26:22
obesity management, especially in rheumatic patients.
26:23
All right, we're going to do one more round of shorties.
26:27
U Mike, what's yours? Yeah, I'm going to share a study that I like.
26:31
Um this is a uh abstract 2803. Um and I I I um I call this the sweaty chat study uh because the first outcome
26:41
measure was supervised weight loss set and the second was light lifestyle counseling chy chat study and what they did is they a small study
26:52
they randomized people to get lifestyle coaching or sort of a more strength-based intervention.
26:56
The primary analysis was was reported a few years back and it looked like the lifestyle intervention more working out.
27:01
You gain a little more muscle, maybe a little more benefit, but both things seem to work here.
27:05
They talked more about the organic biologic effects of this.
27:09
So kind of interesting. We're always talking about like what's really driving this.
27:12
And this paper had just sort of a smorggas board of differences in various cytoines over time.
27:17
So all of your interlucans and things like that.
27:20
And there there were a lot of real biological differences that seemed like they evolved over the 16e study period.
27:24
you know, you had more scinesscent NK cells.
27:26
Um, uh, there was a bunch of different changes in some of the various interlucans, uh, depending on which part of the group you're in, what you were doing.
27:34
And I think this is very tantalizing and hypothesis generating.
27:39
I don't think there's like one specific take-home from this study, but I just keep wondering what's driving this.
27:45
And I appreciate these folks trying to uh give it a give it a whirl.
27:48
Um, and I also like the name of the study.
27:50
Yeah. And I I I went to this plenary um uh pre presentation and and I um the important part is that these are elderly
28:00
RA patients who are either overweight or obese um and they either get you know the lifestyle intervention or the control group and there was
28:10
all these immunologic things while patients got better um and while their muscle strength actually improved uh and this is not an incretant therapy this
28:20
is not a GLP-1 study this is a dietary manipulation and exercise program uh versus those who didn't get it.
28:27
But there were all these imunologic changes that favored the lifestyle.
28:30
And so it kind of says that it is worth talking about this stuff with your patients and making these changes uh and that patients at least their immune function is going to benefit um and then that will parallel their clinical benefits.
28:43
The question is what are the long-term effects?
28:45
How hard is this to implement? you know, it took the basically the Duke Research Institute to to do this kind of detailed study on 20 patients, but um you know, it it is about lifestyle.
28:58
Um Jiha, yeah, I agree. I love that it focused on older adults that it was remote delivery and I think actually one of their other outcomes was that these patients at the end may have required less demar.
29:11
So there was some de intensification of therapy which I think is interesting because there was another obesity related session um size matters where they talked about weight based dosing potentially and obesity meaning that patients clear drugs faster.
29:26
So for examples who 70 kg versus 110 kg the heavier person may need like 40% more drugs and we know all of our drugs
29:33
are fixed dosing right but then with the advent of GLP1 combined with lifestyle as they lose weight the mechanical load comes up I think
29:39
then it gives rise to the interesting question of does this really give us then another opportunity to you know potentially deprescribe or reduce medication
29:46
in our patient population.
29:47
So I think I'd like to see more studies around that for sure in the future and I think that's the intention uh of this uh research group at Duke going forward.
29:57
Um Akquil, what's your shorty? Yeah, so I just wanted to talk about two abstracts kind of along the same lines as abstract 1315 and abstract 0361.
30:07
Essentially it kind of looks at is that you know there's been a lot of buzz and hype around GLP1 here at ACR26.
30:14
But then it comes down to uh what's the real world perception in uh prescription among rheumatologists.
30:20
And so abstract 1315 uh completed a national surveys over a two-year period among rheumatologist asking what is their reported use and perception of GLP-1 in patients with seriatic arthritis.
30:32
And so uh just from the survey they rubinologists at least one-third of rheumatologists perceived at least onethird of their patients are eligible for GLP1
30:40
but actually only 1% actually prescribed a GLP-1 though after the together PSA or sorry though 49% reported they're more likely more likely to prescribe
30:49
in the next 12 months and then with the together PSA announcement it seemed really encouraging for many rheatologists with many foreseeing combined use of
30:58
biologics and GLP1.
31:00
So it's kind of just a take on what what what is the current perceptions and the real world prescription and what it might look like in the future.
31:07
And then there's another abstract 0361 that looked at the real world eligibility and uptake of GLP-1 in a single center uh cohort in a in a combined cardiory clinic at a um academic center in Toronto.
31:19
And essentially they found that nearly 50% of patients with RA, PSA and spondritis were eligible for GLP1.
31:29
But the actual prescription was as low as 11% and uh this was in the past year in in 2026.
31:34
And there's higher prescription among patients with seratic arthritis but lower among patients with RA.
31:39
And when it came to patients that are actually eligible for uh GLP-1, the patients with PSA, these eligible patients uh for GLP1, they had higher disease activity and just a overall worse metabolic profile in terms of lipid and cardiovascular.
31:52
And so really I thought it was just really interesting is that despite the excitement with the uh GLP I think it's kind of what's going to change what's going to convince rheatologists to start prescribing it more how do it fit how do how do we fit into our workflows?
32:03
Um were both of these abstracts uh xus which would influence their use or consideration of GLP1s?
32:12
Sorry, can you repeat that again? Were the were these done in the you said the second one was in Toronto.
32:17
Were the perceptions of rheatologists were those US rheatologists or international?
32:23
Um yeah, US uh rheumat Yeah. US based rheatologist.
32:25
So that's you're right. That's a that's a big issue.
32:28
I mean the numbers are um uh what is it?
32:32
60% of US adults are overweight or obese, but I think RA is over 70%.
32:38
I think PSA is 82%. So they're there, you know, uh this is going to be a consideration.
32:45
Um and the audience is going to have to consider this especially if we're going to get indications u in the next year or two uh for our patients to use these drugs.
32:56
right now the indications by the way you know it's not just you know obesity it is um uh sleep it's obesity it's di diabetes
33:04
obesity sleep apnea and cardiovascular risk patients are also and it's different for the different drugs um and that might be a bit of a
33:16
problem so uh again keep that in mind when you start considering this um we're going to end with Dr. Le's shorty.
33:22
Yeah. So, my shorty is abstract number 1445.
33:25
And um maybe this can be uh one of the expansions or help prescribing because I think prescribing for GLP-1, we know there's a lot of prior authorization and paperwork involved in indication matters.
33:38
So, kind of along with looking at other outcomes of GLP-1, this one is looking at does GLP1 um lead to outcomes in different out pulmonary outcomes in rheumatoid arthritis.
33:49
This is from Jeff Sparts groups um similar to the fracture one using trendex and with real world data.
33:55
This one is trying to compare RA patients with diabetes using GLP1 versus the um depadil peptidase 4 inhibitor DPP4 and their outcomes are looking at incidence of interstitial lung disease or pulmonary hypertension.
34:10
And the study spans data from like 2016 to 2025.
34:14
And they're looking at three-year follow-up for the incidents using survival analysis.
34:17
And they again propensity matched on demographics, medication use, and importantly coorbidity as well.
34:25
And what they showed is that there's no association with a lower risk of um incident.
34:30
However, there are slightly diff um lower risk of pulmonary hypertension with GLP-1.
34:36
But I think what I wanted to just like point out and interject potentially is like the we all know is so underrecognized and it's only since like 2023 when the guidelines came up that I think we have become more diligent.
34:47
So I like that we're starting to look more broadly about how is GLP1 overall impacting our patients?
34:54
Does it lead to you know extra articular manifestation differences?
34:57
But I think as we've heard throughout this group I think we're all questioning okay what is the data?
35:02
What is the study group? What is it really trying to show and what does it mean?
35:06
You know, one of the things that I like like to talk about but I'm not supposed to talk about is the cardiovascular benefit.
35:12
Um, you know, less cardiovascular events, better mortality, but actually that data is not really that strong.
35:18
Um, and I'd like to know what you guys think about that.
35:23
you know, clearly there's really strong data on survival and morbidity with SGLT2 inhibitors um in some of our our diseases, but I don't know that we can sell the utility of these drugs as being cardiorotective or now these other morbidities and and coorbidities.
35:41
Um Mike, what do you think? Oh boy. I I I I think that all of these are probably good for cardio cardoprotective.
35:48
Um, it's hard for me to imagine that your lipids get better, your glucose goes down, you cut a bunch of weight, you're not doing better.
35:58
Um, SGLT2s have a ton of benefits for our patients as well.
36:00
And so, um, I think that rheumatologists as a as a general group need to embrace more cardiac cardoprotective measures and working with our cardiology friends on that.
36:09
And I think this is just another example of that.
36:10
um you know cardiovascular disease is still the number one cause of mortality for most of our patients and making sure we're tying that up as best we can is is critical.
36:19
Akil, what do you think? Yeah. No, I agree and I think you know there was an abstract I did present a video earlier at
36:25
ACR that was that they pulled both the together PSA and the together PSO uh participants actually looked at the cardiovascular benefit and essentially I
36:33
mean they looked at it over a 52 week period and they did find that there was an overall reduction in cardiovascular uh disease and
36:41
um lipid profile and systolic blood pressures.
36:43
But I think, you know, I think we need kind of longer term study long long and real world um uh data kind of longerterm follow-up to really see what are the cardiovascular benefits of GLP-1.
36:52
But I definitely, you know, I do agree with all the points made that I think we, you know, cardiovascular risk is extremely important in
36:59
our patients with romatic diseases and seeing how the impact or the role of uh weight reduction and even medications like GLP and weight reduction
37:08
had its impact on cardiovascular risk I think would be really important and definitely worth uh looking to the future.
37:14
So the enthusiasm of increant therapy has largely been driven by weight loss you know astounding weight loss.
37:22
Um what are the parallels to increin and statin therapy?
37:24
Statin everybody wanted to lower cholesterol but it wasn't until the statin started showing really great more you know survival benefit that they became so
37:34
widespread and so prevalent in management and the question is what would happen if those kind of numbers are all sort of soon to follow
37:43
um not just in in our patients but obviously in diabetics and all people.
37:47
So anyway, I think this is a great discussion.
37:50
A lot of important papers being presented.
37:52
Our faculty, you have no idea how hard they were working for 4 days at ACR 2026 in Orlando.
37:56
And to have them come and share this information with us was just a dream.
38:00
Um Mike Jiha and Akquil, thank you so much.
38:04
Tune in for more of these panel discussions. Bye everyone.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.